Robert I. Griffiths, Michelle L. Gleeson, Joseph Mikhael, Martin H. Dreyling and Mark D. Danese Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma Cancer 118
Version of Record online: 30 MAY 2012 | DOI: 10.1002/cncr.27638
In routine clinical practice, the comparative effectiveness of adding rituximab to first-line chemotherapy for elderly patients who are diagnosed with diffuse large B-cell lymphoma is similar to its efficacy as measured in randomized trials. However, the survival benefits observed in this study do not translate into cost offsets or savings as previously reported by several studies in the peer-reviewed literature.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field